Search

Your search keyword '"Rose, Shawn"' showing total 149 results
Start Over Author "Rose, Shawn"
149 results on '"Rose, Shawn"'

2. Narrative-Focused Video Games as Situated Learning: Media Literacy Implications of Play, Identity, and Perspective Taking

Author

Rose, Shawn

Abstract

With the emergence of more narrative-focused video games, this study attempted to better understand how college students construct meaning through these interactive experiences as a means of understanding social and cultural differences and perspectives. This study explored how playing narrative-focused video games may interconnect with college students' lived experiences, their understanding of others through perspective taking, and their sense of identity in reality and in-game through the lens of media literacy. The theoretical framework utilized in this study drew from situated learning theory and Gee's theory of identity and identity stories. Data collection for this study used multiple data sources including college student focus groups, gameplay observations of students playing "Gone Home," and individual participant interviews. Qualitative, narrative analysis was utilized to explore the identity stories shared by five college student participants as well as the themes that emerged across the various data sources. The results of this study found that participants situated video game narratives within their lived experiences, assimilating the experiences within the game with their own stories and reflections. Preliminary evidence emerged that participants engaged in perspective taking tendencies while playing narrative-focused games; however, this finding appears to be connected with the participant's level of awareness and attention to detail while playing the game. This study also explored concepts of the real, virtual, and projective identities (Gee, 2007). Results found that participants utilized video games that tell stories as a vehicle for exploring their own identity as they project themselves into the characters they embody within the game. While participants primarily described their real identity in regard to discursively established identity traits, video games allowed them to explore alternative points of view. Through gameplay observations and the stories participants shared, evidence in support for the media literacy concepts of play and performance emerged, while the media literacies of simulation and negotiation were less prominently featured. Implications for education and future research are also discussed. [The dissertation citations contained here are published with the permission of ProQuest LLC. Further reproduction is prohibited without permission. Copies of dissertations may be obtained by Telephone (800) 1-800-521-0600. Web page: http://www.proquest.com/en-US/products/dissertations/individuals.shtml.]

Published
2018

4. Mgta-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics, and Pharmacodynamics Initial Findings from a Phase 1/2 Study

Author

Juckett, Mark, primary, Westervelt, Peter, additional, Kebriaei, Partow, additional, Artz, Andrew S., additional, Chan, Onyee, additional, McCarthy, Dr. Philip L., additional, Farag, Sherif S., additional, Singh, Anurag K., additional, Stein, Eytan, additional, Lee, Ji Hyun, additional, Occhiuti, Alison, additional, Tang, Jeanie, additional, Santos, David, additional, Bertelsen, Kirk, additional, Mahender, Balaji, additional, Henry, Nicole, additional, Pardy, Donald, additional, Li, June, additional, Zdybowicz, Christian, additional, and Rose, Shawn, additional

Published
2023
Full Text
View/download PDF

6. A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Mgta-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia

Author

Sharma, Akshay, primary, Manis, John P, additional, Justus, David G., additional, Williams, David A., additional, Efuni, Sergey, additional, Lee, Ji Hyun, additional, Conlin, Erin, additional, Rose, Shawn, additional, Humphrey, Jeffrey, additional, Bertelsen, Kirk, additional, Henry, Nicole, additional, Li, June, additional, Pardy, Donald, additional, Santos, David, additional, Zdybowicz, Christian, additional, Leonard, Alexis, additional, and Tisdale, John, additional

Published
2022
Full Text
View/download PDF

7. Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study

Author

Westervelt, Peter, primary, Kebriaei, Partow, additional, Juckett, Mark, additional, Artz, Andrew S., additional, Chan, Onyee, additional, McCarthy, Philip L., additional, Farag, Sherif S, additional, Singh, Anurag K., additional, Stein, Eytan, additional, Humphrey, Jeffrey, additional, Baeder, William, additional, Lee, Ji Hyun, additional, Occhiuti, Alison, additional, Tang, Jeanie, additional, Santos, David, additional, Bertelsen, Kirk, additional, Mahender, Balaji, additional, Henry, Nicole, additional, and Rose, Shawn, additional

Published
2022
Full Text
View/download PDF

9. Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study

Author

van Vollenhoven, Ronald F., primary, Hahn, Bevra H., additional, Tsokos, George C., additional, Lipsky, Peter, additional, Gordon, Robert M., additional, Fei, Kaiyin, additional, Lo, Kim Hung, additional, Chevrier, Marc, additional, Rose, Shawn, additional, Berry, Pamela, additional, Yao, Zhenling, additional, Karyekar, Chetan S., additional, and Zuraw, Qing, additional

Published
2021
Full Text
View/download PDF

13. Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus

Author

Cesaroni, Matteo, primary, Seridi, Loqmane, additional, Loza, Matthew J., additional, Schreiter, Jessica, additional, Sweet, Kristen, additional, Franks, Carol, additional, Ma, Keying, additional, Orillion, Ashley, additional, Campbell, Kim, additional, M. Gordon, Robert, additional, Branigan, Patrick, additional, Lipsky, Peter, additional, Vollenhoven, Ronald, additional, Hahn, Bevra H., additional, Tsokos, George C., additional, Chevrier, Marc, additional, Rose, Shawn, additional, Baribaud, Frédéric, additional, and Jordan, Jarrat, additional

Published
2021
Full Text
View/download PDF

17. 136 - Mgta-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics, and Pharmacodynamics Initial Findings from a Phase 1/2 Study

Author

Juckett, Mark, Westervelt, Peter, Kebriaei, Partow, Artz, Andrew S., Chan, Onyee, McCarthy, Dr. Philip L., Farag, Sherif S., Singh, Anurag K., Stein, Eytan, Lee, Ji Hyun, Occhiuti, Alison, Tang, Jeanie, Santos, David, Bertelsen, Kirk, Mahender, Balaji, Henry, Nicole, Pardy, Donald, Li, June, Zdybowicz, Christian, and Rose, Shawn

Published
2023
Full Text
View/download PDF

19. Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus

Author

van Vollenhoven, Ronald F., primary, Hahn, Bevra H., additional, Tsokos, George C., additional, Lipsky, Peter, additional, Fei, Kaiyin, additional, Gordon, Robert M., additional, Gregan, Irene, additional, Lo, Kim Hung, additional, Chevrier, Marc, additional, and Rose, Shawn, additional

Published
2020
Full Text
View/download PDF

20. O9 Reduction of interferon-γ and elevated baseline cytotoxic gene expression in the blood associate with ustekinumab response in SLE

Author

Seridi, Loqmane, primary, Cesaroni, Matteo, additional, Loza, Matt, additional, Schreiter, Jessica, additional, Sweet, Kristen, additional, Campbell, Kim, additional, Lipsky, Peter, additional, Vollenhoven, Ronald van, additional, Hahn, Bevra H, additional, Tsokos, George C, additional, Chevrier, Marc, additional, Rose, Shawn, additional, Baribaud, Frédéric, additional, and Jordan, Jarrat, additional

Published
2020
Full Text
View/download PDF

22. Challenges in the Development of drugs for Systemic Lupus Erythematosus: A Regulatory Perspective

Author

Del Vecchio, Alfred, Chevrier, Marc, Elias, Drew, O'Dowd, Liza, Paxson, Bethany, Rose, Shawn, Shields-Tuttle, Kimberly, and Vermeulen, Rob

Abstract

Systemic lupus erythematosus (SLE) is a debilitating disease that affects at least 5 million people worldwide. Currently, there are limited approved treatment options for patients with SLE, and a great need remains for therapies to achieve important treatment goals such as reductions in flares, prevention of organ damage, clinical low disease activity or remission. The purpose of this article is to review the current health authority guidance for the development of drugs to treat SLE and discuss some of the challenges in the development of drugs for SLE from a regulatory perspective. Given the substantial number of failed late-stage clinical trials in this indication despite the inclusion of large numbers of subjects, reviewing the regulatory guidance and complexities surrounding the development of drugs for the treatment of SLE is crucial to understand the complexities of the disease itself and the challenges and limitations to conducting successful trials evaluating the impact of treatment of new agents in SLE. As only one new drug (belimumab, trade name BENLYSTA®) with a novel mechanism of action has been approved over the last six decades, the prescribing information for belimumab will be reviewed in the context of the guidance.https://doi.org/10.21423/jrs-v07delvecchio

Published
2019
Full Text
View/download PDF

23. Development of a new humanized mouse model to study acute inflammatory arthritis

Author

Misharin Alexander V, Haines G, Rose Shawn, Gierut Angelical K, Hotchkiss Richard S, and Perlman Harris

Subjects
Humanized mouse, Leukocytes, Rheumatoid arthritis, Etanercept, Medicine
Abstract

Abstract Background Substantial advances have been generated in understanding the pathogenesis of rheumatoid arthritis (RA). Current murine models of RA-like disease have provided great insights into the molecular mechanism of inflammatory arthritis due to the use of genetically deficient or transgenic mice. However, these studies are limited by differences that exist between human and murine immune systems. Thus, the development of an animal model that utilizes human immune cells, will afford the opportunity to study their function in the initiation and propagation of inflammatory arthritis. Methods One to two-day old irradiated NOD-scid IL2rγnull (NSG) mice were reconstituted with human CD34+ cord blood stem cells. Leukocytes were analyzed by flow cytometry and circulating antibodies were determined by ELISA. Arthritis was induced by injecting complete Freund’s adjuvant into knee or ankle joints. Mice were also treated with the TNF inhibitor, Etanercept, or PBS and joints were analyzed histologically. Results Humanized mice were established with high reconstitution rates and were able to spontaneously produce human immunoglobulins as well as specific IgG in response to immunization. Intraperitoneal injection of thioglycolate or injection of complete Freund’s adjuvant into joints resulted in migration of human immune cells to the injected sites. Arthritic humanized mice treated with Etanercept had markedly less inflammation, which was associated with decreased total numbers of human CD45+ cells, including human lymphocytes and neutrophils. Conclusions The humanized mouse model is a new model to study inflammatory arthritis disease using human leukocytes without rejection of engrafted tissue. Future studies may adapt this system to incorporate RA patient cord blood and develop a chimeric animal model of inflammatory arthritis using genetically predisposed immune cells.

Published
2012
Full Text
View/download PDF

24. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

Author

Burke, James R., primary, Cheng, Lihong, additional, Gillooly, Kathleen M., additional, Strnad, Joann, additional, Zupa-Fernandez, Adriana, additional, Catlett, Ian M., additional, Zhang, Yifan, additional, Heimrich, Elizabeth M., additional, McIntyre, Kim W., additional, Cunningham, Mark D., additional, Carman, Julie A., additional, Zhou, Xiadi, additional, Banas, Dana, additional, Chaudhry, Charu, additional, Li, Sha, additional, D’Arienzo, Celia, additional, Chimalakonda, Anjaneya, additional, Yang, XiaoXia, additional, Xie, Jenny H., additional, Pang, Jian, additional, Zhao, Qihong, additional, Rose, Shawn M., additional, Huang, Jinwen, additional, Moslin, Ryan M., additional, Wrobleski, Stephen T., additional, Weinstein, David S., additional, and Salter-Cid, Luisa M., additional

Published
2019
Full Text
View/download PDF

27. OP0278 BIOMARKER PROFILING REVEALS NOVEL MECHANISTIC INSIGHTS INTO USTEKINUMAB THERAPEUTIC RESPONSES IN SYSTEMIC LUPUS ERYTHEMATOSUS

Author

Cesaroni, Matteo, primary, Seridi, Loqmane, additional, Jordan, Jarrat, additional, Sweet, Kristen, additional, Keying, MA, additional, Franks, Carol, additional, Schreiter, Jessica, additional, Lipsky, Peter, additional, Vollenhoven, Ronald van, additional, Hahn, Bevra H., additional, Rose, Shawn, additional, Baribaud, Frederic, additional, Loza, Matthew J, additional, Campbell, Kim, additional, and Tsokos, George, additional

Published
2019
Full Text
View/download PDF

28. OP0041 MAINTENANCE OF EFFICACY AND SAFETY AND REDUCTION OF BILAG FLARES WITH USTEKINUMAB, AN INTERLEUKIN-12/23 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): 1-YEAR RESULTS OF A PHASE 2, RANDOMIZED PLACEBO-CONTROLLED, CROSSOVER STUDY

Author

Vollenhoven, Ronald van, primary, Tsokos, George, additional, Gordon, Robert, additional, Lo, Kim Hung, additional, Irene Gregan, Y, additional, Fei, Kaiyin, additional, Rose, Shawn, additional, and Hahn, Bevra H., additional

Published
2019
Full Text
View/download PDF

29. 251 Type II but not type I interferon signifies clinical response to ustekinumab in patients with systemic lupus erythematosus

Author

Jordan, Jarrat, primary, Sweet, Kristen, additional, Cesaroni, Matteo, additional, Ma, Keying, additional, Franks, Carol, additional, Seridi, Loqmane, additional, Schreiter, Jessica, additional, Gordon, Robert, additional, Lipsky, Peter, additional, Vollenhoven, Ronald van, additional, Tsokos, George C, additional, Hahn, Bevra H, additional, Rose, Shawn, additional, Baribaud, Frédéric, additional, Loza, Matthew J, additional, and Campbell, Kim, additional

Published
2019
Full Text
View/download PDF

32. Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.

Author

Vollenhoven, Ronald F., Hahn, Bevra H., Tsokos, George C., Lipsky, Peter, Fei, Kaiyin, Gordon, Robert M., Gregan, Irene, Lo, Kim Hung, Chevrier, Marc, and Rose, Shawn

Subjects
THERAPEUTIC use of monoclonal antibodies, SUBCUTANEOUS injections, CROSSOVER trials, INTRAVENOUS therapy, LONGITUDINAL method, MEDICAL cooperation, MONOCLONAL antibodies, PLACEBOS, RESEARCH, STATISTICAL sampling, SYSTEMIC lupus erythematosus, RANDOMIZED controlled trials, TREATMENT effectiveness, BLIND experiment
Abstract

Objective: To evaluate the efficacy and safety of ustekinumab through 1 year in a phase II trial in patients with systemic lupus erythematosus (SLE). Methods: Eligible patients were diagnosed as having clinically active SLE (based on Systemic Lupus International Collaborating Clinics criteria), despite standard background therapy. Active disease was defined by an SLE Disease Activity Index 2000 (SLEDAI‐2K) score of ≥6 as well as having ≥1 British Isles Lupus Assessment Group (BILAG) A organ domain score and/or ≥2 BILAG B organ domain scores present at screening. Patients (n = 102) were randomized (3:2) to receive either ustekinumab (~6 mg/kg of single intravenous infusion at week 0, then 90‐mg subcutaneous injections every 8 weeks beginning at week 8) or a matching placebo added to standard therapy. At week 24, the placebo group crossed over to receive a subcutaneous 90‐mg dose of ustekinumab every 8 weeks, and the original ustekinumab group continued to receive therapy through week 40. Maintenance of efficacy was assessed using the SLEDAI‐2K, the SLE Responder Index 4 (SRI‐4), physician global assessment, and mucocutaneous and joint disease measures in a modified intent‐to‐treat population. Results: SRI‐4 response rates were significantly greater in the ustekinumab group (62%) versus the placebo group (33%) in the week 24 primary end point analysis (P = 0.006) and were maintained at week 48 (63.3%) in the ustekinumab group. In the ustekinumab group, response rates across other disease measures were also maintained through week 48. Among patients in the placebo group who crossed over to ustekinumab treatment (n = 33), increased response rates across efficacy measures were noted. Among all ustekinumab‐treated patients, 81.7% had ≥1 adverse event (AE), and 15.1% had ≥1 serious AE through week 56. No deaths, malignancies, opportunistic infections, or tuberculosis cases were observed. Conclusion: Ustekinumab provided sustained clinical benefit in patients with SLE through 1 year, with a safety profile consistent with other indications. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

33. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

Author

van Vollenhoven, Ronald F, primary, Hahn, Bevra H, additional, Tsokos, George C, additional, Wagner, Carrie L, additional, Lipsky, Peter, additional, Touma, Zahi, additional, Werth, Victoria P, additional, Gordon, Robert M, additional, Zhou, Bei, additional, Hsu, Benjamin, additional, Chevrier, Marc, additional, Triebel, Manon, additional, Jordan, Jarrat L, additional, and Rose, Shawn, additional

Published
2018
Full Text
View/download PDF

34. Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis

Author

Baumer, Yvonne, primary, Ng, Qimin, additional, Sanda, Gregory E., additional, Dey, Amit K., additional, Teague, Heather L., additional, Sorokin, Alexander V., additional, Dagur, Pradeep K., additional, Silverman, Joanna I., additional, Harrington, Charlotte L., additional, Rodante, Justin A., additional, Rose, Shawn M., additional, Varghese, Nevin J., additional, Belur, Agastya D., additional, Goyal, Aditya, additional, Gelfand, Joel M., additional, Springer, Danielle A., additional, Bleck, Christopher K.E., additional, Thomas, Crystal L., additional, Yu, Zu-Xi, additional, Winge, Mårten C.G., additional, Kruth, Howard S., additional, Marinkovich, M. Peter, additional, Joshi, Aditya A., additional, Playford, Martin P., additional, and Mehta, Nehal N., additional

Published
2018
Full Text
View/download PDF

35. MOESM3 of ApoE deficiency exacerbates the development and sustainment of a semi-chronic K/BxN serum transfer-induced arthritis model

Author

Archer, Amy, Saber, Rana, Rose, Shawn, Shaffer, Alexander, Misharin, Alexander, FuNien Tsai, G. Haines III, Dominguez, Salina, Eren, Mesut, Vaughan, Douglas, Cuda, Carla, and Perlman, Harris

Abstract

Additional file 3. Alteration of levels of circulating cytokines/chemokines in C57BL/6 and ApoE−/− mice with induction of arthritis. Serum levels from non-arthritic and arthritic C57BL/6 (control, n = 2 non-arthritic and n = 13 arthritic) and ApoE−/− (n = 3 non-arthritic and n = 6 arthritic) mice at 4–6 months. Data are represented as mean ± SEM. * denotes statistically significant differences. *p

Published
2016
Full Text
View/download PDF

36. ApoE deficiency exacerbates the development and sustainment of a semi-chronic K/BxN serum transfer-induced arthritis model

Author

Archer, Amy M., primary, Saber, Rana, additional, Rose, Shawn, additional, Shaffer, Alexander, additional, Misharin, Alexander V., additional, Tsai, FuNien, additional, Haines III, G. Kenneth, additional, Dominguez, Salina, additional, Eren, Mesut, additional, Vaughan, Douglas E., additional, Cuda, Carla M., additional, and Perlman, Harris, additional

Published
2016
Full Text
View/download PDF

37. Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study

Author

Naik, Haley B., primary, Natarajan, Balaji, additional, Stansky, Elena, additional, Ahlman, Mark A., additional, Teague, Heather, additional, Salahuddin, Taufiq, additional, Ng, Qimin, additional, Joshi, Aditya A., additional, Krishnamoorthy, Parasuram, additional, Dave, Jenny, additional, Rose, Shawn M., additional, Doveikis, Julia, additional, Playford, Martin P., additional, Prussick, Ronald B., additional, Ehrlich, Alison, additional, Kaplan, Mariana J., additional, Lockshin, Benjamin N., additional, Gelfand, Joel M., additional, and Mehta, Nehal N., additional

Published
2015
Full Text
View/download PDF

38. High Resolution MRI of Arthritic Murine Ankle Joints Discriminates Inflammation and Bone Destruction in a Quantifiable Manner

Author

Rose, Shawn, Waters, Emily A., Haney, Chad R., Meade, C. Thomas J., and Perlman, Harris

Subjects
Inflammation, Radiography, Mice, Disease Progression, Animals, Bone Resorption, Arthritis, Experimental, Magnetic Resonance Imaging, Article, Ankle Joint
Abstract

The ability to noninvasively monitor the development of inflammatory arthritis longitudinally has become increasingly important in experimental rheumatology. Magnetic resonance imaging (MRI) allows for detailed examination of anatomic structures, as well as the assessment of joint and soft tissue inflammation. The aim of this study was to extend the use of MRI to include quantitative measurements of bone destruction in murine ankle joints.Joint disease was measured serially using clinical, histologic, in vivo imaging system (IVIS), micro-computed tomography (micro-CT), and MRI techniques in mouse ankle joints, using the K/BxN serum transfer-induced acute arthritis and K/BxA(g7) chronic arthritis models. Ankle joint MRI was performed using a gradient-echo pulse sequence to evaluate bone destruction and a spin-echo sequence to evaluate inflammation (long T2 signal).Arthritic mice, as compared to control mice, demonstrated increased disease severity according to clinical, histologic, IVIS, and MRI measures. Following induction of arthritis, the majority of volume expansion of the long T2 signal occurred in a juxtaarticular, rather than intrarticular, manner within the ankle joints. Bone destruction in K/BxA(g7) mouse ankle joints was readily detectible by MRI. Linear regression analyses demonstrated significant correlations between the clinical score and joint radiance intensity assessed by IVIS, between the ankle joint width and increased long T2 signal on MRI, and between the bone volume obtained by micro-CT and bone volume obtained by MRI.MRI is an optimal technology for anatomic localization of articular and soft tissue changes during the development and progression of inflammatory arthritis. Future studies may combine MRI with in vivo labeling agents to investigate joint disease in a cell type-specific manner.

Published
2013

39. Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation

Author

Zidar, David A., primary, Juchnowski, Steven, additional, Ferrari, Brian, additional, Clagett, Brian, additional, Pilch-Cooper, Heather A., additional, Rose, Shawn, additional, Rodriguez, Benigno, additional, McComsey, Grace A., additional, Sieg, Scott F., additional, Mehta, Nehal N., additional, Lederman, Michael M., additional, and Funderburg, Nicholas T., additional

Published
2015
Full Text
View/download PDF

42. Characterization of immune cells in psoriatic adipose tissue

Author

Rose, Shawn, primary, Stansky, Elena, additional, Dagur, Pradeep K, additional, Samsel, Leigh, additional, Weiner, Elizabeth, additional, Jahanshad, Amir, additional, Doveikis, Julia, additional, Naik, Haley B, additional, Playford, Martin P, additional, McCoy, J Philip, additional, and Mehta, Nehal N, additional

Published
2014
Full Text
View/download PDF

44. VASCULAR INFLAMMATION BY [18F]-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY IS ASSOCIATED WITH AORTIC WALL PROPERTIES BY MAGNETIC RESONANCE IMAGING

Author

Sadek, Ahmed, primary, Dave, Jenny, additional, Hasan, Josh, additional, Krishnamoorthy, Parasuram, additional, Rose, Shawn, additional, Naik, Haley, additional, Weiner, Elizabeth, additional, Ahlman, Mark A., additional, Bluemke, David A., additional, and Mehta, Nehal N., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results